Of note, in the 12 month follow-ups, the mean NAFLD fibrosis score (NFS) was higher in patients with decreased serum GDF15 (−1.85 vs. −2.32; p = 0.028) (Figure 2C). This evidence concerns the gene GDF15 and metabolic dysfunction-associated steatotic liver disease.